Objective:
To evaluate the safety, tolerability, and efficacy of PER-001 in patients with moderate-to-severe nonproliferative diabetic retinopathy.
Key Findings:
- PER-001 was safe and well tolerated with no serious drug-related adverse events.
- Patients treated with PER-001 showed improvement in low-luminance contrast sensitivity compared to the control group.
- Visual field improvement was observed in the low-dose group, while the control group remained unchanged.
- Structural improvements in ischemia, leakage, and microaneurysms were noted in PER-001 treated groups.
Interpretation:
This study presents the first functional improvement in diabetic retinopathy, indicating potential for PER-001 as a treatment option.
Limitations:
- Small sample size of 27 patients.
- Short duration of the study (6 months).
- Further studies needed to confirm long-term efficacy and safety.
Conclusion:
PER-001 demonstrates promising functional and structural improvements in diabetic retinopathy, warranting further investigation in larger trials.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
